Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach
- PMID: 34050823
- DOI: 10.1007/s00441-021-03461-4
Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach
Abstract
The umbilical cord has been proved to be an easy-access, reliable, and useful source of mesenchymal stem cells (MSC) for clinical applications due to its primitive, immunomodulatory, non-immunogenic, secretory and paracrine, migratory, proliferative, and multipotent properties. This set of characteristics has recently attracted great research interest in the fields of nanotechnology and regenerative medicine and cellular therapy. Accumulating evidence supports a pronounced therapeutic potential of MSC in many different pathologies, from hematology to immunology, wound-healing, tissue regeneration, and oncology. Diabetes mellitus, branded the epidemic of the century, is considered a chronic metabolic disorder, representing a major burden for health system sustainability and an important public health challenge to modern societies. The available treatments for type 2 diabetes mellitus (T2DM) still rely mainly on combinations of oral antidiabetic agents with lifestyle and nutritional adjustments. Despite the continuous development of novel and better hypoglycemic drugs, their efficacy is limited in the installment and progression of silent T2DM complications. T2DM comorbidities and mortality rates still make it a serious, common, costly, and long-term manageable disease. Recently, experimental models, preclinical observations, and clinical studies have provided some insights and preliminary promising results using umbilical cord MSCs to treat and manage diabetes. This review focuses on the latest research and applications of human-derived umbilical cord MSC in the treatment and management of T2DM, exploring and systematizing the key effects of both umbilical cord MSC and its factor-rich secretome accordingly with the major complications associated to T2DM.
Keywords: Cell therapy; Clinical application; Regenerative medicine; Type 2 diabetes mellitus; Umbilical cord mesenchymal cells; Vascular complications.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice.Int Immunopharmacol. 2018 Jul;60:235-245. doi: 10.1016/j.intimp.2018.04.051. Epub 2018 May 25. Int Immunopharmacol. 2018. PMID: 29778021
-
Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?Tissue Eng Part B Rev. 2014 Oct;20(5):523-44. doi: 10.1089/ten.TEB.2013.0664. Epub 2014 Apr 22. Tissue Eng Part B Rev. 2014. PMID: 24552279 Review.
-
Tailoring cell therapies for diabetic metabolic phenotypes: a comparative study on the efficacy of various umbilical cord-derived cell regimens.Stem Cells Transl Med. 2025 Feb 11;14(2):szae083. doi: 10.1093/stcltm/szae083. Stem Cells Transl Med. 2025. PMID: 39560969 Free PMC article.
-
Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances.Int J Med Sci. 2023 Sep 11;20(11):1492-1507. doi: 10.7150/ijms.87472. eCollection 2023. Int J Med Sci. 2023. PMID: 37790847 Free PMC article. Review.
-
Reversion of early- and late-stage β-cell dedifferentiation by human umbilical cord-derived mesenchymal stem cells in type 2 diabetic mice.Cytotherapy. 2021 Jun;23(6):510-520. doi: 10.1016/j.jcyt.2021.01.005. Epub 2021 Mar 16. Cytotherapy. 2021. PMID: 33736932
Cited by
-
Human umbilical cord mesenchymal stem cells (hUC-MSCs) alleviate paclitaxel-induced spermatogenesis defects and maintain male fertility.Biol Res. 2023 Aug 13;56(1):47. doi: 10.1186/s40659-023-00459-w. Biol Res. 2023. PMID: 37574561 Free PMC article.
-
Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model.Stem Cell Res Ther. 2022 Nov 12;13(1):517. doi: 10.1186/s13287-022-03201-7. Stem Cell Res Ther. 2022. PMID: 36371344 Free PMC article.
-
Anti-inflammatory and immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages.J Nanobiotechnology. 2022 Jan 20;20(1):38. doi: 10.1186/s12951-021-01236-1. J Nanobiotechnology. 2022. PMID: 35057811 Free PMC article.
-
Human umbilical cord mesenchymal stem cells reduce platelet α-granule release in rats via the AKT/MEK/ERK pathway during acute exposure to high-altitude hypoxia.World J Stem Cells. 2025 Jun 26;17(6):106272. doi: 10.4252/wjsc.v17.i6.106272. World J Stem Cells. 2025. PMID: 40585956 Free PMC article.
-
Comparison between Intra-Articular Injection of Infrapatellar Fat Pad (IPFP) Cell Concentrates and IPFP-Mesenchymal Stem Cells (MSCs) for Cartilage Defect Repair of the Knee Joint in Rabbits.Stem Cells Int. 2021 Jul 27;2021:9966966. doi: 10.1155/2021/9966966. eCollection 2021. Stem Cells Int. 2021. PMID: 34367294 Free PMC article.
References
-
- Adamiak M, Cheng G, Bobis-Wozowicz S, Zhao L, Kedracka-Krok S, Samanta A, Karnas E, Xuan YT, Skupien-Rabian B, Chen X, Jankowska U, Girgis M, Sekula M, Davani A, Lasota S, Vincent RJ, Sarna M, Newell KL, Wang OL, Dudley N, Madeja Z, Dawn B, Zuba-Surma EK (2018) Induced pluripotent stem cell (iPSC)-derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. Circ Res 122:296–309 - PubMed - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical